The latest price target for Ginkgo Bioworks Holdings (NYSE:DNA) was reported by TD Cowen on September 20, 2024. The analyst firm set a price target for $10.00 expecting DNA to rise to within 12 months (a possible 26.42% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for Ginkgo Bioworks Holdings (NYSE:DNA) was provided by TD Cowen, and Ginkgo Bioworks Holdings maintained their buy rating.

There is no last upgrade for Ginkgo Bioworks Holdings

The last downgrade for Ginkgo Bioworks Holdings Inc happened on May 15, 2024 when BTIG changed their price target from N/A to N/A for Ginkgo Bioworks Holdings Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ginkgo Bioworks Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ginkgo Bioworks Holdings was filed on September 20, 2024 so you should expect the next rating to be made available sometime around September 20, 2025.

While ratings are subjective and will change, the latest Ginkgo Bioworks Holdings (DNA) rating was a maintained with a price target of $3.00 to $10.00. The current price Ginkgo Bioworks Holdings (DNA) is trading at is $7.91, which is within the analyst’s predicted range.